Rectovaginal fistula in a cervical cancer patient treated with sequential radiotherapy and bevacizumab: A dose-volume analysis

Kento Tomizawa; Ken Ando; Hirofumi Shimada; Takuya Kaminuma; Kazutoshi Murata; Takahiro Oike; Tatsuya Ohno

doi:10.1002/ccr3.3955

Rectovaginal fistula in a cervical cancer patient treated with sequential radiotherapy and bevacizumab: A dose-volume analysis

Clin Case Rep. 2021 Feb 23;9(4):2099-2104. doi: 10.1002/ccr3.3955. eCollection 2021 Apr.

Authors

Kento Tomizawa¹, Ken Ando¹, Hirofumi Shimada², Takuya Kaminuma¹, Kazutoshi Murata^{1

3}, Takahiro Oike^{1

2}, Tatsuya Ohno^{1

2}

Affiliations

¹ Department of Radiation Oncology Gunma University Graduate School of Medicine Gunma Japan.
² Gunma University Heavy Ion Medical Center Gunma Japan.
³ QST Hospital National Institutes for Quantum and Radiological Science and Technology Chiba Japan.

Abstract

Bevacizumab is a monoclonal antibody against vascular endothelial growth factor that exerts antitumor effect by preventing tumor angiogenesis. Gastrointestinal fistula is a common side effect of bevacizumab in combination with radiotherapy. This case of rectovaginal fistula indicates that the side effect may be unpredictable by the conventional dose-volume parameters for the rectum.

Keywords: bevacizumab; cervical cancer; dose‐volume analysis; radiation; rectovaginal fistula.

Publication types

Case Reports